伤寒结合疫苗的实地有效性：2018年纳维孟买儿科TCV活动。

IF 1.9 4区医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH American Journal of Tropical Medicine and Hygiene Pub Date : 2024-08-13 DOI:10.4269/ajtmh.24-0181

Kashmira Date, Christopher LeBoa, Seth A Hoffman, Pradeep Haldar, Pauline Harvey, Qian An, Chenhua Zhang, Vijay N Yewale, Savita Daruwalla, Dhanya Dharmapalan, Jeetendra Gavhane, Shrikrishna Joshi, Rajesh Rai, Varsha Rathod, Keertana Shetty, Divyalatha S Warrier, Shalini Yadav, Rahul Shimpi, Niniya Jayaprasad, Lily Horng, Kirsten Fagerli, Priyanka Borhade, Debjit Chakraborty, Arun Katkar, Abhishek Kunwar, Jason R Andrews, Sunil Bahl, Pankaj Bhatnagar, Shanta Dutta, Stephen P Luby

{"title":"伤寒结合疫苗的实地有效性：2018年纳维孟买儿科TCV活动。","authors":"Kashmira Date, Christopher LeBoa, Seth A Hoffman, Pradeep Haldar, Pauline Harvey, Qian An, Chenhua Zhang, Vijay N Yewale, Savita Daruwalla, Dhanya Dharmapalan, Jeetendra Gavhane, Shrikrishna Joshi, Rajesh Rai, Varsha Rathod, Keertana Shetty, Divyalatha S Warrier, Shalini Yadav, Rahul Shimpi, Niniya Jayaprasad, Lily Horng, Kirsten Fagerli, Priyanka Borhade, Debjit Chakraborty, Arun Katkar, Abhishek Kunwar, Jason R Andrews, Sunil Bahl, Pankaj Bhatnagar, Shanta Dutta, Stephen P Luby","doi":"10.4269/ajtmh.24-0181","DOIUrl":null,"url":null,"abstract":"Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05-0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0-95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.","PeriodicalId":7752,"journal":{"name":"American Journal of Tropical Medicine and Hygiene","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign.\",\"authors\":\"Kashmira Date, Christopher LeBoa, Seth A Hoffman, Pradeep Haldar, Pauline Harvey, Qian An, Chenhua Zhang, Vijay N Yewale, Savita Daruwalla, Dhanya Dharmapalan, Jeetendra Gavhane, Shrikrishna Joshi, Rajesh Rai, Varsha Rathod, Keertana Shetty, Divyalatha S Warrier, Shalini Yadav, Rahul Shimpi, Niniya Jayaprasad, Lily Horng, Kirsten Fagerli, Priyanka Borhade, Debjit Chakraborty, Arun Katkar, Abhishek Kunwar, Jason R Andrews, Sunil Bahl, Pankaj Bhatnagar, Shanta Dutta, Stephen P Luby\",\"doi\":\"10.4269/ajtmh.24-0181\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05-0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0-95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.\",\"PeriodicalId\":7752,\"journal\":{\"name\":\"American Journal of Tropical Medicine and Hygiene\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Tropical Medicine and Hygiene\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4269/ajtmh.24-0181\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Tropical Medicine and Hygiene","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4269/ajtmh.24-0181","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

摘要

Typbar-TCV® 是一种伤寒结合疫苗（TCV），于 2017 年通过了世界卫生组织的预认证。我们评估了它在 2018 年 9 月至 2020 年 7 月期间针对印度纳维孟买 9 个月至 14 岁儿童开展的大规模疫苗接种计划中的有效性。我们将来自六个临床地点的实验室确诊伤寒病例与年龄匹配的社区对照组进行了比较。在 38 例病例中，有 3 例（8.6%）通过活动接受了 TCV，而在 140 例对照中，有 53 例（37%）接受了 TCV。接种过疫苗的儿童发生伤寒的调整后几率比为 0.16（95% CI：0.05-0.55），相当于 83.7% 的疫苗有效率（95% CI：45.0-95.3）。在这次大规模的公共部门疫苗接种中，Typbar-TCV 的接种效果与之前的随机对照试验相似，这为政策制定者提供了保证，即 TCV 在大规模接种中是有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign.

Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05-0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0-95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Tropical Medicine and Hygiene 医学-公共卫生、环境卫生与职业卫生

CiteScore

6.20

自引率

3.00%

发文量

508

审稿时长

3 months

期刊介绍： The American Journal of Tropical Medicine and Hygiene, established in 1921, is published monthly by the American Society of Tropical Medicine and Hygiene. It is among the top-ranked tropical medicine journals in the world publishing original scientific articles and the latest science covering new research with an emphasis on population, clinical and laboratory science and the application of technology in the fields of tropical medicine, parasitology, immunology, infectious diseases, epidemiology, basic and molecular biology, virology and international medicine. The Journal publishes unsolicited peer-reviewed manuscripts, review articles, short reports, images in Clinical Tropical Medicine, case studies, reports on the efficacy of new drugs and methods of treatment, prevention and control methodologies,new testing methods and equipment, book reports and Letters to the Editor. Topics range from applied epidemiology in such relevant areas as AIDS to the molecular biology of vaccine development. The Journal is of interest to epidemiologists, parasitologists, virologists, clinicians, entomologists and public health officials who are concerned with health issues of the tropics, developing nations and emerging infectious diseases. Major granting institutions including philanthropic and governmental institutions active in the public health field, and medical and scientific libraries throughout the world purchase the Journal. Two or more supplements to the Journal on topics of special interest are published annually. These supplements represent comprehensive and multidisciplinary discussions of issues of concern to tropical disease specialists and health issues of developing countries